02617.HK
TransThera Sciences (Nanjing) Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 8.40
−2.95%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- -8.5%
- EBIT
- -4.7%
- Net income
- -7.8%
- EPS
- -10.1%
- Free cash flow
- +6.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026